APA

Hochberg M. C., Tive L. A., Abramson S. B., Vignon E., Verburg K. M., West C. R., Smith M. D. & Hungerford D. S. (20160614). When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. : Arthritis & rheumatology (Hoboken, N.J.).

Chicago

Hochberg Marc C, Tive Leslie A, Abramson Steven B, Vignon Eric, Verburg Kenneth M, West Christine R, Smith Michael D and Hungerford David S. 20160614. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. : Arthritis & rheumatology (Hoboken, N.J.).

Harvard

Hochberg M. C., Tive L. A., Abramson S. B., Vignon E., Verburg K. M., West C. R., Smith M. D. and Hungerford D. S. (20160614). When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. : Arthritis & rheumatology (Hoboken, N.J.).

MLA

Hochberg Marc C, Tive Leslie A, Abramson Steven B, Vignon Eric, Verburg Kenneth M, West Christine R, Smith Michael D and Hungerford David S. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. : Arthritis & rheumatology (Hoboken, N.J.). 20160614.